Advertisement

Mechanisms of Mutant LRRK2 Neurodegeneration

  • Mark R. CooksonEmail author
Part of the Advances in Neurobiology book series (NEUROBIOL, volume 14)

Abstract

LRRK2 mutations are associated with the loss of neurons, that is to say toxicity, in patients and in experimental model systems. However, the mechanisms by which mutations can be linked to neurodegeneration are not fully defined. Here I will argue that mechanism in this context encompasses a variety of levels of information. Mutations or alterations in gene expression at a genetic level are one set of mechanisms that are reflected at the biochemical level likely in enhanced or persistent function of LRRK2. By impacting cellular pathways, prominently including changes in autophagy but also microtubule function, mitochondria and protein synthesis, in neurons and immune cells, the LRRK2 brain is primed for neurodegeneration in an age-dependent manner. These concepts have implications for not only modeling LRRK2 disease but also perhaps for Parkinson’s disease more generally, including the development of therapeutic modalities.

Keywords

α-Synuclein Gene expression GTPase Kinase Mutations Pleomorphic risk locus Rab7L1 

Abbreviations

BAC

Bacterial artificial chromosome

COR

C-terminal of ROC

GWAS

Genome-wide association study

LRRK2

Leucine-rich repeat kinase 2

MAPT

Microtubule-associated protein tau

PD

Parkinson’s disease

ROC

Ras of complex proteins

SNP

Single-nucleotide polymorphism

Notes

Acknowledgments

This research was supported entirely by the Intramural Research Program of the NIH and the National Institute on Aging.

Conflict of Interest

The author declares no conflicts of interest.

References

  1. 1.
    Zimprich A, Biskup S, Leitner P et al (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601–607CrossRefPubMedGoogle Scholar
  2. 2.
    Paisán-Ruíz C, Jain S, Evans EW et al (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 44:595–600CrossRefPubMedGoogle Scholar
  3. 3.
    Benamer HTS, de Silva R (2010) LRRK2 G2019S in the North African population: a review. Eur Neurol 63:321–325CrossRefPubMedGoogle Scholar
  4. 4.
    Inzelberg R, Hassin-Baer S, Jankovic J (2014) Genetic movement disorders in patients of Jewish ancestry. JAMA Neurol 71:1567–1572CrossRefPubMedGoogle Scholar
  5. 5.
    Peeraully T, Tan EK (2012) Genetic variants in sporadic Parkinson’s disease: East vs West. Parkinsonism Relat Disord 18(Suppl 1):S63–S65CrossRefPubMedGoogle Scholar
  6. 6.
    Tan E-K (2007) The role of common genetic risk variants in Parkinson disease. Clin Genet 72:387–393CrossRefPubMedGoogle Scholar
  7. 7.
    Bardien S, Lesage S, Brice A, Carr J (2011) Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson’s disease. Parkinsonism Relat Disord 17:501–508CrossRefPubMedGoogle Scholar
  8. 8.
    Nalls MA, Pankratz N, Lill CM et al (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet 46:989–993CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Singleton A, Hardy J (2011) A generalizable hypothesis for the genetic architecture of disease: pleomorphic risk loci. Hum Mol Genet 20:R158–R162CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Cookson MR, Hardy J, Lewis PA (2008) Genetic neuropathology of Parkinson’s disease. Int J Clin Exp Pathol 1:217–231PubMedPubMedCentralGoogle Scholar
  11. 11.
    Lewis PA, Greggio E, Beilina A et al (2007) The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun 357:668–671CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Li X, Tan Y-C, Poulose S et al (2007) Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson’s disease R1441C/G mutants. J Neurochem 103:238–247CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Daniëls V, Vancraenenbroeck R, Law BMH et al (2011) Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J Neurochem 116:304–315CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Guo L, Gandhi PN, Wang W et al (2007) The Parkinson’s disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res 313:3658–3670CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Liao J, Wu C-X, Burlak C et al (2014) Parkinson disease-associated mutation R1441H in LRRK2 prolongs the “active state” of its GTPase domain. Proc Natl Acad Sci U S A 111:4055–4060CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Greggio E, Cookson MR (2009) Leucine-rich repeat kinase 2 mutations and Parkinson’s disease: three questions. ASN Neuro. doi: 10.1042/AN20090007 PubMedPubMedCentralGoogle Scholar
  17. 17.
    Ray S, Bender S, Kang S et al (2014) The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity. J Biol Chem 289:13042–13053CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Cookson MR (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson’s disease. Nat Rev Neurosci 11:791–797CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Greggio E, Jain S, Kingsbury A et al (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23:329–341CrossRefPubMedGoogle Scholar
  20. 20.
    Smith WW, Pei Z, Jiang H et al (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9:1231–1233CrossRefPubMedGoogle Scholar
  21. 21.
    Skibinski G, Nakamura K, Cookson MR, Finkbeiner S (2014) Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies. J Neurosci Off J Soc Neurosci 34:418–433CrossRefGoogle Scholar
  22. 22.
    Yao C, Johnson WM, Gao Y et al (2012) Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity. Hum Mol Genet 22(2):328–344. doi: 10.1093/hmg/dds431 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Liu Z, Hamamichi S, Lee BD et al (2011) Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson’s disease models. Hum Mol Genet 20:3933–3942CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Lee BD, Shin J-H, VanKampen J et al (2010) Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson’s disease. Nat Med 16:998–1000CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    West AB (2014) Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic. Mov Disord 30(2):180–189. doi: 10.1002/mds.26075 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    MacLeod D, Dowman J, Hammond R et al (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52:587–593CrossRefPubMedGoogle Scholar
  27. 27.
    Nichols RJ, Dzamko N, Morrice NA et al (2010) 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson’s disease-associated mutations and regulates cytoplasmic localization. Biochem J 430:393–404CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Jaleel M, Nichols RJ, Deak M et al (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson’s disease mutants affect kinase activity. Biochem J 405:307–317CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Rudenko IN, Kaganovich A, Hauser DN et al (2012) The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson’s disease is a partial loss-of-function mutation. Biochem J 446:99–111CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Rudenko IN, Chia R, Cookson MR (2012) Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson’s disease? BMC Med 10:20CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Biosa A, Trancikova A, Civiero L et al (2013) GTPase activity regulates kinase activity and cellular phenotypes of Parkinson’s disease-associated LRRK2. Hum Mol Genet 22:1140–1156CrossRefPubMedGoogle Scholar
  32. 32.
    Ko HS, Bailey R, Smith WW et al (2009) CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc Natl Acad Sci U S A 106:2897–2902CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Herzig MC, Kolly C, Persohn E et al (2011) LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet 20:4209–4223CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Westerlund M, Belin AC, Anvret A et al (2008) Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: Implications for Parkinson’s disease. Neuroscience 152:429–436CrossRefPubMedGoogle Scholar
  35. 35.
    Mandemakers W, Snellinx A, O’Neill MJ, de Strooper B (2012) LRRK2 expression is enriched in the striosomal compartment of mouse striatum. Neurobiol Dis 48:582–593CrossRefPubMedGoogle Scholar
  36. 36.
    Melrose H, Lincoln S, Tyndall G et al (2006) Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience 139:791–794CrossRefPubMedGoogle Scholar
  37. 37.
    Simón-Sánchez J, Herranz-Pérez V, Olucha-Bordonau F, Pérez-Tur J (2006) LRRK2 is expressed in areas affected by Parkinson’s disease in the adult mouse brain. Eur J Neurosci 23:659–666CrossRefPubMedGoogle Scholar
  38. 38.
    West AB, Cowell RM, Daher JPL et al (2014) Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents. J Comp Neurol 522:2465–2480CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    West AB, Moore DJ, Choi C et al (2007) Parkinson’s disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16:223–232CrossRefPubMedGoogle Scholar
  40. 40.
    Iaccarino C, Crosio C, Vitale C et al (2007) Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet 16:1319–1326CrossRefPubMedGoogle Scholar
  41. 41.
    Li Y, Liu W, Oo TF et al (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson’s disease. Nat Neurosci 12:826–828CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Tagliaferro P, Kareva T, Oo TF et al (2015) An early axonopathy in a hLRRK2(R1441G) transgenic model of Parkinson disease. Neurobiol Dis 82:359–371CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Lin X, Parisiadou L, Gu X-L et al (2009) Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson’s-disease-related mutant alpha-synuclein. Neuron 64:807–827CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Ramonet D, Daher JPL, Lin BM et al (2011) Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One 6(4), e18568. doi: 10.1371/journal.pone.0018568 CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Garcia-Miralles M, Coomaraswamy J, Häbig K et al (2015) No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts. PLoS One 10, e0118947. doi: 10.1371/journal.pone.0118947 CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Maekawa T, Mori S, Sasaki Y et al (2012) The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities. Mol Neurodegener 7:15CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Lee J-W, Tapias V, Di Maio R et al (2015) Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats. Neurobiol Aging 36:505–518CrossRefPubMedGoogle Scholar
  48. 48.
    Dusonchet J, Kochubey O, Stafa K et al (2011) A rat model of progressive nigral neurodegeneration induced by the Parkinson’s disease-associated G2019S mutation in LRRK2. J Neurosci Off J Soc Neurosci 31:907–912CrossRefGoogle Scholar
  49. 49.
    Tsika E, Nguyen APT, Dusonchet J et al (2015) Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson’s disease. Neurobiol Dis 77:49–61CrossRefPubMedGoogle Scholar
  50. 50.
    Beccano-Kelly DA, Volta M, Munsie LN et al (2015) LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory. Hum Mol Genet 24:1336–1349CrossRefPubMedGoogle Scholar
  51. 51.
    Yue M, Hinkle KM, Davies P et al (2015) Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol Dis 78:172–195CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Sanchez G, Varaschin RK, Büeler H et al (2014) Unaltered striatal dopamine release levels in young Parkin knockout, Pink1 knockout, DJ-1 knockout and LRRK2 R1441G transgenic mice. PLoS One 9, e94826CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Plowey ED, Cherra SJ, Liu Y-J, Chu CT (2008) Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem 105:1048–1056CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Manzoni C, Mamais A, Dihanich S et al (2013) Pathogenic Parkinson’s disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation. Biochem Biophys Res Commun 441:862–866CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Sánchez-Danés A, Richaud-Patin Y, Carballo-Carbajal I et al (2012) Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson’s disease. EMBO Mol Med 4:380–395CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Cherra SJ, Steer E, Gusdon AM et al (2013) Mutant LRRK2 elicits calcium imbalance and depletion of dendritic mitochondria in neurons. Am J Pathol 182:474–484CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Mortiboys H, Furmston R, Bronstad G et al (2015) UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2(G2019S) carriers and in vivo. Neurology 85:846–852CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Su Y-C, Qi X (2013) Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation. Hum Mol Genet 22:4545–4561CrossRefPubMedGoogle Scholar
  59. 59.
    Wang X, Yan MH, Fujioka H et al (2012) LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum Mol Genet 21:1931–1944CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Gehrke S, Imai Y, Sokol N, Lu B (2010) Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 466:637–641CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Martin I, Kim JW, Lee BD et al (2014) Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson’s disease. Cell 157:472–485CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Liu G-H, Qu J, Suzuki K et al (2012) Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature 491:603–607CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Tsika E, Kannan M, Foo CS-Y et al (2014) Conditional expression of Parkinson’s disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration. Neurobiol Dis 71:345–358CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Moehle MS, Webber PJ, Tse T et al (2012) LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci Off J Soc Neurosci 32:1602–1611CrossRefGoogle Scholar
  65. 65.
    Gillardon F, Schmid R, Draheim H (2012) Parkinson’s disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience 208:41–48CrossRefPubMedGoogle Scholar
  66. 66.
    Choi I, Kim B, Byun J-W et al (2015) LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase. Nat Commun 6:8255CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Kim B, Yang M-S, Choi D et al (2012) Impaired inflammatory responses in murine lrrk2-knockdown brain microglia. PLoS One 7, e34693CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Russo I, Berti G, Plotegher N et al (2015) Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-κB p50 signaling in cultured microglia cells. J Neuroinflammation 12:230CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Schapansky J, Nardozzi JD, Felizia F, Lavoie MJ (2014) Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy. Hum Mol Genet 23(16):4201–4214. doi: 10.1093/hmg/ddu138 CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Matt SM, Johnson RW (2015) Neuro-immune dysfunction during brain aging: new insights in microglial cell regulation. Curr Opin Pharmacol 26:96–101CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Saha S, Ash PEA, Gowda V et al (2015) Mutations in LRRK2 potentiate age-related impairment of autophagic flux. Mol Neurodegener 10:26CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Schapansky J, Nardozzi JD, LaVoie MJ (2015) The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson’s disease. Neuroscience 302:74–88CrossRefPubMedGoogle Scholar
  73. 73.
    Jorgensen ND, Peng Y, Ho CC-Y et al (2009) The WD40 domain is required for LRRK2 neurotoxicity. PLoS One 4, e8463.1CrossRefGoogle Scholar
  74. 74.
    Hsu CH, Chan D, Greggio E et al (2010) MKK6 binds and regulates expression of Parkinson’s disease-related protein LRRK2. J Neurochem 112:1593–1604CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Xiong Y, Yuan C, Chen R et al (2012) ArfGAP1 is a GTPase activating protein for LRRK2: reciprocal regulation of ArfGAP1 by LRRK2. J Neurosci Off J Soc Neurosci 32:3877–3886CrossRefGoogle Scholar
  76. 76.
    Stafa K, Trancikova A, Webber PJ et al (2012) GTPase activity and neuronal toxicity of Parkinson’s disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet 8, e1002526.1CrossRefGoogle Scholar
  77. 77.
    Civiero L, Cirnaru MD, Beilina A et al (2015) Leucine-rich repeat kinase 2 interacts with p21-activated kinase 6 to control neurite complexity in mammalian brain. J Neurochem 135:1242–1256. doi: 10.1111/jnc.13369 CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Lavalley NJ, Slone SR, Ding H et al (2015) 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening. Hum Mol Genet 25(1):109–122. doi: 10.1093/hmg/ddv453 CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Cookson MR (2009) alpha-Synuclein and neuronal cell death. Mol Neurodegener 4:9CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Daher JPL, Volpicelli-Daley LA, Blackburn JP et al (2014) Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proc Natl Acad Sci U S A 111:9289–9294CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Daher JPL, Abdelmotilib HA, Hu X et al (2015) Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration. J Biol Chem 290:19433–19444CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Daher JPL, Pletnikova O, Biskup S et al (2012) Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2. Hum Mol Genet 21:2420–2431CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Herzig MC, Bidinosti M, Schweizer T et al (2012) High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain. PLoS One 7, e36581CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Beilina A, Cookson MR (2015) Genes associated with Parkinson’s disease: regulation of autophagy and beyond. J Neurochem 139(Suppl 1):91–107. doi: 10.1111/jnc.13266 PubMedGoogle Scholar
  85. 85.
    Goedert M (2015) NEURODEGENERATION. Alzheimer’s and Parkinson’s diseases: the prion concept in relation to assembled Aβ, tau, and α-synuclein. Science 349:1255555CrossRefPubMedGoogle Scholar
  86. 86.
    Wallings R, Manzoni C, Bandopadhyay R (2015) Cellular processes associated with LRRK2 function and dysfunction. FEBS J 282:2806–2826CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Kawakami F, Yabata T, Ohta E et al (2012) LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PLoS One 7, e30834CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Lin C-H, Tsai P-I, Wu R-M, Chien C-T (2010) LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3β. J Neurosci Off J Soc Neurosci 30:13138–13149CrossRefGoogle Scholar
  89. 89.
    Beilina A, Rudenko IN, Kaganovich A et al (2014) Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc Natl Acad Sci U S A 111(7):2626–2631. doi: 10.1073/pnas.1318306111 CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    MacLeod DA, Rhinn H, Kuwahara T et al (2013) RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson’s disease risk. Neuron 77:425–439CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Laboratory of NeurogeneticsNational Institute on Aging, National Institutes of HealthBethesdaUSA

Personalised recommendations